Financhill
Sell
46

CRSP Quote, Financials, Valuation and Earnings

Last price:
$56.81
Seasonality move :
-15.72%
Day range:
$55.88 - $59.48
52-week range:
$30.04 - $63.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.68x
Volume:
2.9M
Avg. volume:
3.4M
1-year change:
-0.02%
Market cap:
$4.9B
Revenue:
$35M
EPS (TTM):
-$4.52

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CRSP
CRISPR Therapeutics AG
$13M -$1.30 -96.36% -7.71% $81.75
ACIU
AC Immune SA
$381.2K -$0.23 215.05% -22.94% $9.18
NTLA
Intellia Therapeutics
$12.4M -$0.98 77.46% -32.4% $37.30
NVS
Novartis AG
$13.7B $2.23 8.26% 47.31% $113.44
ONC
BeOne Medicines
$1.3B $0.27 29.74% -70.04% $330.95
VRTX
Vertex Pharmaceuticals
$3B $4.60 9.9% 1.98% $500.23
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CRSP
CRISPR Therapeutics AG
$56.80 $81.75 $4.9B -- $0.00 0% --
ACIU
AC Immune SA
$2.04 $9.18 $205.2M -- $0.00 0% 6.27x
NTLA
Intellia Therapeutics
$11.54 $37.30 $1.2B -- $0.00 0% 25.53x
NVS
Novartis AG
$121.02 $113.44 $239B 18.94x $3.99 3.3% 4.58x
ONC
BeOne Medicines
$250.30 $330.95 $27.1B -- $0.00 0% 6.43x
VRTX
Vertex Pharmaceuticals
$468.85 $500.23 $120.4B 26.10x $0.00 0% 10.94x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CRSP
CRISPR Therapeutics AG
-- 2.371 -- 21.97x
ACIU
AC Immune SA
-- 3.489 -- 1.50x
NTLA
Intellia Therapeutics
-- 2.464 -- 4.57x
NVS
Novartis AG
43.44% 0.140 13.49% 0.50x
ONC
BeOne Medicines
20.88% 0.624 3.14% 1.64x
VRTX
Vertex Pharmaceuticals
-- -0.256 -- 2.12x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CRSP
CRISPR Therapeutics AG
-$57.5M -$148.4M -18.65% -18.65% -184.54% -$54.2M
ACIU
AC Immune SA
-- -$21.5M -42.34% -42.34% -1916.67% -$21.3M
NTLA
Intellia Therapeutics
-- -$120.8M -56.9% -56.9% -726.57% -$149.7M
NVS
Novartis AG
$10.4B $4.7B 18.39% 30.96% 34.34% $2.2B
ONC
BeOne Medicines
$952.3M $11.1M -8.9% -11.54% 0.99% -$72.3M
VRTX
Vertex Pharmaceuticals
$2.4B $1B -6.04% -6.04% 26.48% $778.2M

CRISPR Therapeutics AG vs. Competitors

  • Which has Higher Returns CRSP or ACIU?

    AC Immune SA has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -1922.12%. CRISPR Therapeutics AG's return on equity of -18.65% beat AC Immune SA's return on equity of -42.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
  • What do Analysts Say About CRSP or ACIU?

    CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 43.93%. On the other hand AC Immune SA has an analysts' consensus of $9.18 which suggests that it could grow by 349.89%. Given that AC Immune SA has higher upside potential than CRISPR Therapeutics AG, analysts believe AC Immune SA is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    11 10 1
    ACIU
    AC Immune SA
    3 0 0
  • Is CRSP or ACIU More Risky?

    CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison AC Immune SA has a beta of 1.618, suggesting its more volatile than the S&P 500 by 61.81%.

  • Which is a Better Dividend Stock CRSP or ACIU?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or ACIU?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than AC Immune SA quarterly revenues of $1.1M. CRISPR Therapeutics AG's net income of -$136M is lower than AC Immune SA's net income of -$21.2M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 6.27x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
    ACIU
    AC Immune SA
    6.27x -- $1.1M -$21.2M
  • Which has Higher Returns CRSP or NTLA?

    Intellia Therapeutics has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -687.61%. CRISPR Therapeutics AG's return on equity of -18.65% beat Intellia Therapeutics's return on equity of -56.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
    NTLA
    Intellia Therapeutics
    -- -$1.10 $779.9M
  • What do Analysts Say About CRSP or NTLA?

    CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 43.93%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.30 which suggests that it could grow by 223.33%. Given that Intellia Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Intellia Therapeutics is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    11 10 1
    NTLA
    Intellia Therapeutics
    18 6 0
  • Is CRSP or NTLA More Risky?

    CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

  • Which is a Better Dividend Stock CRSP or NTLA?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or NTLA?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Intellia Therapeutics quarterly revenues of $16.6M. CRISPR Therapeutics AG's net income of -$136M is lower than Intellia Therapeutics's net income of -$114.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 25.53x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
    NTLA
    Intellia Therapeutics
    25.53x -- $16.6M -$114.3M
  • Which has Higher Returns CRSP or NVS?

    Novartis AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 26.48%. CRISPR Therapeutics AG's return on equity of -18.65% beat Novartis AG's return on equity of 30.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
    NVS
    Novartis AG
    76.31% $1.82 $67.9B
  • What do Analysts Say About CRSP or NVS?

    CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 43.93%. On the other hand Novartis AG has an analysts' consensus of $113.44 which suggests that it could fall by -6.26%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    11 10 1
    NVS
    Novartis AG
    0 8 2
  • Is CRSP or NVS More Risky?

    CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.101%.

  • Which is a Better Dividend Stock CRSP or NVS?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.3% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CRSP or NVS?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Novartis AG quarterly revenues of $13.6B. CRISPR Therapeutics AG's net income of -$136M is lower than Novartis AG's net income of $3.6B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 4.58x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
    NVS
    Novartis AG
    4.58x 18.94x $13.6B $3.6B
  • Which has Higher Returns CRSP or ONC?

    BeOne Medicines has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 0.11%. CRISPR Therapeutics AG's return on equity of -18.65% beat BeOne Medicines's return on equity of -11.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
    ONC
    BeOne Medicines
    85.23% -- $4.4B
  • What do Analysts Say About CRSP or ONC?

    CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 43.93%. On the other hand BeOne Medicines has an analysts' consensus of $330.95 which suggests that it could grow by 32.22%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines, analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    11 10 1
    ONC
    BeOne Medicines
    15 1 0
  • Is CRSP or ONC More Risky?

    CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

  • Which is a Better Dividend Stock CRSP or ONC?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or ONC?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. CRISPR Therapeutics AG's net income of -$136M is lower than BeOne Medicines's net income of $1.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 6.43x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
    ONC
    BeOne Medicines
    6.43x -- $1.1B $1.3M
  • Which has Higher Returns CRSP or VRTX?

    Vertex Pharmaceuticals has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 23.33%. CRISPR Therapeutics AG's return on equity of -18.65% beat Vertex Pharmaceuticals's return on equity of -6.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
    VRTX
    Vertex Pharmaceuticals
    86.9% $2.49 $16.5B
  • What do Analysts Say About CRSP or VRTX?

    CRISPR Therapeutics AG has a consensus price target of $81.75, signalling upside risk potential of 43.93%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.23 which suggests that it could grow by 6.69%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRSP
    CRISPR Therapeutics AG
    11 10 1
    VRTX
    Vertex Pharmaceuticals
    15 14 1
  • Is CRSP or VRTX More Risky?

    CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

  • Which is a Better Dividend Stock CRSP or VRTX?

    CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRSP or VRTX?

    CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. CRISPR Therapeutics AG's net income of -$136M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 10.94x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
    VRTX
    Vertex Pharmaceuticals
    10.94x 26.10x $2.8B $646.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock